DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Bon, Giulia, Krasniqi, Eriseld, Porru, Manuela, D'Ambrosio, Lorenzo, Scalera, Stefano, Maugeri-Saccà, Marcello, Di Lisa, Francesca Sofia, Filomeno, Lorena, Arcuri, Teresa, Botticelli, Andrea, Santini, Daniele, Fabbri, Maria Agnese, D'Auria, Giuliana, Pulito, Claudio, Blandino, Giovanni, Marchiò, Caterina, Barba, Maddalena, Ciliberto, Gennaro, Vici, Patrizia, Pizzuti, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539861/
https://www.ncbi.nlm.nih.gov/pubmed/37769528
http://dx.doi.org/10.1016/j.neo.2023.100937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539861/
https://www.ncbi.nlm.nih.gov/pubmed/37769528
http://dx.doi.org/10.1016/j.neo.2023.100937

Ejemplares similares